This article is more than 5 years old. Information may no longer be current.

Regenera, Alcon enter licensing agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PERTH, Australia — Alcon has licensed a product “that is used to assist in visualization of the vitreous fluid” during vitrectomy, according to a press release from Regenera.

Alcon will pay Regenera up-front license fees and milestone and royalty payments, and it will hold the license until the product’s patent expires, according to the release. Alcon has worldwide rights to the product, which has not yet received regulatory approval, according to Regenera.

The global license will allow Alcon to manufacture, market and distribute the product as a “visualization device” in vitrectomy surgery, according to the release.